Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Has Average Target Price of $595.20

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have received an average rating of “Hold” from the thirteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $602.27.

Several brokerages recently commented on MEDP. Truist Financial increased their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. TD Cowen upped their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. BMO Capital Markets upped their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Robert W. Baird increased their price target on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Finally, Royal Bank Of Canada raised their price target on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: UBS upgraded Medpace from “sell” to “hold” and raised its price target to $673 from $405. The new target is above recent trading levels, suggesting UBS sees reduced downside risk. UBS upgrades Medpace and raises price target
• Positive Sentiment: Medpace’s latest quarterly results remain supportive of its growth story: revenue rose 17.2% year over year to $707.3 million, while earnings of $4.25 per share exceeded the $3.98 consensus estimate. Fiscal 2026 earnings guidance also remains intact.
• Neutral Sentiment: Analyst sentiment is broadly mixed, with most firms maintaining “hold” ratings. The consensus price target is approximately $602.27, close to recent levels, indicating that much of the company’s growth may already be reflected in its valuation.
• Negative Sentiment: CEO August Troendle sold 21,966 shares for approximately $13.7 million on September 30, after selling 26,701 shares worth about $16.6 million on September 29. The combined sales totaled roughly $30.3 million and materially reduced his direct ownership. Additional smaller sales were also reported, raising concerns about insider confidence and contributing to the stock’s weakness. Troendle nevertheless retains a substantial stake. Medpace CEO stock sale SEC filing

Insider Transactions at Medpace

In other Medpace news, CEO August Troendle sold 49,018 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the sale, the chief executive officer directly owned 433,372 shares in the company, valued at approximately $272,205,286.92. This trade represents a 10.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders sold 336,140 shares of company stock valued at $208,008,328. Corporate insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new stake in shares of Medpace in the second quarter worth approximately $1,323,047,000. Madison Asset Management LLC bought a new position in Medpace during the second quarter valued at approximately $128,956,000. Bank of America Corp DE bought a new position in Medpace during the second quarter valued at approximately $116,891,000. American Capital Management Inc. purchased a new stake in Medpace in the second quarter worth approximately $111,329,000. Finally, Franklin Resources Inc. boosted its holdings in Medpace by 158.6% in the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after purchasing an additional 183,645 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 0.2%

Medpace stock opened at $599.47 on Tuesday. Medpace has a 12 month low of $373.00 and a 12 month high of $677.90. The company has a market capitalization of $16.73 billion, a price-to-earnings ratio of 35.14, a price-to-earnings-growth ratio of 2.67 and a beta of 1.18. The business’s fifty day simple moving average is $599.95 and its two-hundred day simple moving average is $521.18.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue was up 17.2% on a year-over-year basis. During the same period last year, the company earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts predict that Medpace will post 17.54 EPS for the current year.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.